Metastatic breast cancer (MBC) is associated with a poor prognosis, and patients often develop refractory or resistant disease, adverse events, depression, and financial hardship. Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN®, office practice nurse in the Outpatient Breast Medicine Service at Memorial Sloan Kettering Cancer Center, spoke with i3 Health about challenging patient questions and the importance of multidisciplinary care in the management of patients with MBC. What are some of the most ...
Cyclin dependent kinase (CDK)4/6 inhibitors have produced tremendous advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer through their targeting of hormone signals that stimulate the proliferation of cancer cells. Three CDK4/6 inhibitors have been FDA approved for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer: palbociclib (Ibrance®, Pfizer Inc.), ribociclib (Kisqali®, Novar...